Arctiin protects against cardiac hypertrophy through inhibiting MAPKs and AKT signaling pathways
Arctiin protects against cardiac hypertrophy through inhibiting MAPKs and AKT signaling pathways
复制标题
DOI：
10.1016/j.jphs.2017.05.012
复制
发表时间：
2017-11-01
影响因子：
3.5
通讯作者：
Tang, Qi-Zhu
中科院分区：
文献类型：
--
作者：
Li, Jing;Yuan, Yu-Pei;Tang, Qi-Zhu
目的：丝裂原活化蛋白激酶(MAPKs)和蛋白激酶B(AKT)通路是真核细胞中必不可少的细胞内信号通路，尤其是作为心肌肥厚的调节因子。以往的研究表明，牛至苷作为二年生成熟牛磺酸的有效成分，可能通过下调MAPKs和AKT通路的激活而显示出强大的抗炎和抗过敏活性。然而，对其对心肌肥厚的影响却知之甚少。因此，本研究旨在探讨牛至苷是否具有减轻心脏肥厚的作用。一般方法：从术后1周开始，以牛至苷(80 mg/kg)灌胃，每日1次，连续3周。然后，小鼠接受由主动脉环扎术(AB)产生的慢性压力超负荷或假手术(对照组)。超声心动图评价心功能。结果：牛至苷可减轻AB诱导的心肌肥厚，并抑制体内心肌纤维化和胶原堆积。牛至苷还抑制MAPKs的激活，AKT是在肥大刺激下发生的。结论：牛至苷通过阻断MAPKs和AKT信号通路，改善心功能，预防心肌肥厚的发生。(C)2017年作者。由爱思唯尔B.V.代表日本药理学会制作和主办。
Purpose: The mitogen-activated protein kinases (MAPKs) and protein kinase B (AKT) pathways have emerged as essential intracellular signaling pathways in eukaryotic cells, particularly as regulators of cardiac hypertrophy. Previous studies indicated that arctiin, an active ingredient of biennial dried ripe burdock, could exhibit potent anti-inflammatory and anti-allergic activities via down-regulating the activation of MAPKs and AKT pathways. However, little is known about its effects on cardiac hypertrophy. Therefore, the present study aimed to explore whether arctiin could attenuate cardiac hypertrophy.General methods: Arctiin (80 mg/kg) was administered by oral gavage once daily for 3 weeks from 1 week after surgery. Then, the mice were subjected to either chronic pressure overload generated by aortic banding (AB) or sham surgery (control group). Cardiac function was assessed by echocardiography.Findings: The results indicated that arctiin attenuated cardiac hypertrophy induced by AB, and suppressed cardiac fibrosis and accumulation of collagen in vivo. Arctiin also inhibit the activation of MAPKs and AKT occurs in response to hypertrophic stimuli. Arctiin attenuated phenylephrine-induced hypertrophy of myocytes in vitro.Conclusions: In conclusion, arctiin can improve cardiac function and prevent the development of cardiac hypertrophy by blocking the MAPKs and AKT signaling pathways. (c) 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological Society.